[HTML][HTML] Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
U Hennrich, K Kopka - Pharmaceuticals, 2019 - mdpi.com
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT),
Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of …
Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of …
Radiotheranostics: a roadmap for future development
Radiotheranostics, injectable radiopharmaceuticals with antitumour effects, have seen rapid
development over the past decade. Although some formulations are already approved for …
development over the past decade. Although some formulations are already approved for …
Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology
JF Gomes Marin, RF Nunes, AM Coutinho… - Radiographics, 2020 - pubs.rsna.org
Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …
[HTML][HTML] Radiolabeled somatostatin analogs—a continuously evolving class of radiopharmaceuticals
M Fani, R Mansi, GP Nicolas, D Wild - Cancers, 2022 - mdpi.com
Simple Summary Somatostatin receptors (SSTs) are of particular interest in oncology
because these proteins are overexpressed on the cell membranes of different human …
because these proteins are overexpressed on the cell membranes of different human …
Targeted radionuclide therapy: a historical and personal review
SJ Goldsmith - Seminars in Nuclear Medicine, 2020 - Elsevier
This review traces the development of targeted radionuclide therapy (TRT)(the Magic Bullet)
from the discovery of radioactivity in nature and the subsequent discovery of artificial …
from the discovery of radioactivity in nature and the subsequent discovery of artificial …
Recent advances in radiometals for combined imaging and therapy in cancer
N Herrero Álvarez, D Bauer, J Hernández‐Gil… - …, 2021 - Wiley Online Library
Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic
applications. The imaging modalities positron emission tomography (PET) and single …
applications. The imaging modalities positron emission tomography (PET) and single …
Sensing the unreachable: challenges and opportunities in biofilm detection
Bacteria can attach to essentially all materials and form multicellular biofilms with high-level
tolerance to antimicrobials. Detrimental biofilms are responsible for a variety of problems …
tolerance to antimicrobials. Detrimental biofilms are responsible for a variety of problems …
Polysaccharide-based theranostic systems for combined imaging and cancer therapy: Recent advances and challenges
Designing novel systems for efficient cancer treatment and improving the quality of life for
patients is a prime requirement in the healthcare sector. In this regard, theranostics have …
patients is a prime requirement in the healthcare sector. In this regard, theranostics have …
[HTML][HTML] Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a
very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding …
very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding …
Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies
L Lee, T Ito, RT Jensen - Expert review of anticancer therapy, 2018 - Taylor & Francis
Introduction: Recently, there have been a number of advances in imaging pancreatic
neuroendocrine tumors (panNETs), as well as other neuroendocrine tumors (NETs), which …
neuroendocrine tumors (panNETs), as well as other neuroendocrine tumors (NETs), which …